Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 Jun 3;310(6992):1433–1438. doi: 10.1136/bmj.310.6992.1433

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.

I M Anderson 1, B M Tomenson 1
PMCID: PMC2549813  PMID: 7613276

Abstract

OBJECTIVE--To assess treatment discontinuation rates with selective serotonin reuptake inhibitors compared with tricyclic antidepressants. DESIGN--Meta-analysis of 62 randomised controlled trials. SUBJECTS--6029 patients with major unipolar depression. MAIN OUTCOME MEASURES--Pooled risk ratios for drop out rates with respect to all cases of discontinuation and those due to side effects and treatment failure. RESULTS--The total discontinuation rate was 10% lower with selective serotonin reuptake inhibitors than with tricyclic antidepressants (risk ratio 0.90; 95% confidence interval 0.84 to 0.97) and the drop out rate due to side effects was 25% lower (risk ratio 0.75; 0.66 to 0.84). There was no significant difference between drug classes in the drop out rates for treatment failure. The risk ratios for drop out did not differ significantly between individual selective serotonin reuptake inhibitors. CONCLUSIONS--Selective serotonin reuptake inhibitors are better tolerated than tricyclic antidepressants as measured by total numbers of drop outs. The definite advantage to selective serotonin reuptake inhibitors is explained by fewer drop outs due to side effects. The overall difference, however, is comparatively small and may not be clinically relevant. Analyses of cost effectiveness should not overestimate the advantage to selective serotonin reuptake inhibitors.

Full text

PDF
1433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamura A. C., Percudani M., Guercetti G., Invernizzi G. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):103–106. [PubMed] [Google Scholar]
  2. Ayuso-Gutiérrez J. L., Ramos-Brieva J. A. The course of manic-depressive illness. A comparative study of bipolar I and bipolar II patients. J Affect Disord. 1982 Mar;4(1):9–14. doi: 10.1016/0165-0327(82)90013-1. [DOI] [PubMed] [Google Scholar]
  3. Ballinger B. R., Feely J. Antidepressants. Br Med J (Clin Res Ed) 1983 Jun 11;286(6381):1885–1887. doi: 10.1136/bmj.286.6381.1885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand Suppl. 1989;350:141–142. doi: 10.1111/j.1600-0447.1989.tb07196.x. [DOI] [PubMed] [Google Scholar]
  5. Battegay R., Hager M., Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic (pilot study). Neuropsychobiology. 1985;13(1-2):31–37. doi: 10.1159/000118159. [DOI] [PubMed] [Google Scholar]
  6. Bignamini A., Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 4):37–41. doi: 10.1097/00004850-199206004-00008. [DOI] [PubMed] [Google Scholar]
  7. Bremner J. D. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1984 Oct;45(10):414–419. [PubMed] [Google Scholar]
  8. Bressa G. M., Brugnoli R., Pancheri P. A double-blind study of fluoxetine and imipramine in major depression. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):69–73. [PubMed] [Google Scholar]
  9. Byerley W. F., Reimherr F. W., Wood D. R., Grosser B. I. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol. 1988 Apr;8(2):112–115. [PubMed] [Google Scholar]
  10. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):32–37. [PubMed] [Google Scholar]
  11. Cohn C. K., Shrivastava R., Mendels J., Cohn J. B., Fabre L. F., Claghorn J. L., Dessain E. C., Itil T. M., Lautin A. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990 Dec;51 (Suppl B):28–33. [PubMed] [Google Scholar]
  12. Cohn J. B., Crowder J. E., Wilcox C. S., Ryan P. J. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull. 1990;26(2):185–189. [PubMed] [Google Scholar]
  13. Cohn J. B., Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):26–31. [PubMed] [Google Scholar]
  14. Coleman B. S., Block B. A. Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6):475–478. doi: 10.1016/s0278-5846(82)80132-2. [DOI] [PubMed] [Google Scholar]
  15. Corne S. J., Hall J. R. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int Clin Psychopharmacol. 1989 Jul;4(3):245–254. doi: 10.1097/00004850-198907000-00007. [DOI] [PubMed] [Google Scholar]
  16. Debus J. R., Rush A. J., Himmel C., Tyler D., Polatin P., Weissenburger J. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988 Nov;49(11):422–426. [PubMed] [Google Scholar]
  17. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  18. Dominguez R. A., Goldstein B. J., Jacobson A. F., Steinbook R. M. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry. 1985 Mar;46(3):84–87. [PubMed] [Google Scholar]
  19. Dorman T. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 4):53–58. [PubMed] [Google Scholar]
  20. Dunbar G. C., Cohn J. B., Fabre L. F., Feighner J. P., Fieve R. R., Mendels J., Shrivastava R. K. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry. 1991 Sep;159:394–398. doi: 10.1192/bjp.159.3.394. [DOI] [PubMed] [Google Scholar]
  21. Dunner D. L., Cohn J. B., Walshe T., 3rd, Cohn C. K., Feighner J. P., Fieve R. R., Halikas J. P., Hartford J. T., Hearst E. D., Settle E. C., Jr Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992 Feb;53 (Suppl):57–60. [PubMed] [Google Scholar]
  22. Fabre L. F., Scharf M. B., Itil T. M. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry. 1991 Jun;52 (Suppl):62–67. [PubMed] [Google Scholar]
  23. Falk W. E., Rosenbaum J. F., Otto M. W., Zusky P. M., Weilburg J. B., Nixon R. A. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol. 1989 Oct-Dec;2(4):208–214. doi: 10.1177/089198878900200407. [DOI] [PubMed] [Google Scholar]
  24. Feighner J. P. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985 Sep;46(9):369–372. [PubMed] [Google Scholar]
  25. Feighner J. P. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 4):31–35. doi: 10.1097/00004850-199206004-00007. [DOI] [PubMed] [Google Scholar]
  26. Feighner J. P., Boyer W. F., Meredith C. H., Hendrickson G. G. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol. 1989 Jul;4(3):239–244. doi: 10.1097/00004850-198907000-00006. [DOI] [PubMed] [Google Scholar]
  27. Feighner J. P., Boyer W. F., Merideth C. H., Hendrickson G. G. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol. 1989 Apr;4(2):127–134. doi: 10.1097/00004850-198904000-00004. [DOI] [PubMed] [Google Scholar]
  28. Feighner J. P., Boyer W. F. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand Suppl. 1989;350:125–129. doi: 10.1111/j.1600-0447.1989.tb07190.x. [DOI] [PubMed] [Google Scholar]
  29. Feighner J. P., Cohn J. B. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):20–25. [PubMed] [Google Scholar]
  30. Feighner J. P., Cohn J. B., Fabre L. F., Jr, Fieve R. R., Mendels J., Shrivastava R. K., Dunbar G. C. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord. 1993 Jun;28(2):71–79. doi: 10.1016/0165-0327(93)90035-i. [DOI] [PubMed] [Google Scholar]
  31. Feighner J. P., Gardner E. A., Johnston J. A., Batey S. R., Khayrallah M. A., Ascher J. A., Lineberry C. G. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991 Aug;52(8):329–335. [PubMed] [Google Scholar]
  32. Ferreri M. Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):97–101. [PubMed] [Google Scholar]
  33. Gagiano C. A., Müller P. G., Fourie J., Le Roux J. F. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand Suppl. 1989;350:130–131. doi: 10.1111/j.1600-0447.1989.tb07191.x. [DOI] [PubMed] [Google Scholar]
  34. Gasperini M., Gatti F., Bellini L., Anniverno R., Smeraldi E. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients. Neuropsychobiology. 1992;26(4):186–192. doi: 10.1159/000118918. [DOI] [PubMed] [Google Scholar]
  35. Gonella G., Baignoli G., Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Curr Med Res Opin. 1990;12(3):177–184. doi: 10.1185/03007999009111499. [DOI] [PubMed] [Google Scholar]
  36. Gravem A., Amthor K. F., Astrup C., Elgen K., Gjessing L. R., Gunby B., Pettersen R. D., Kyrdalen L., Vaadal J., Ofsti E. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand. 1987 May;75(5):478–486. doi: 10.1111/j.1600-0447.1987.tb02821.x. [DOI] [PubMed] [Google Scholar]
  37. Guillibert E., Pelicier Y., Archambault J. C., Chabannes J. P., Clerc G., Desvilles M., Guibert M., Pagot R., Poisat J. L., Thobie Y. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl. 1989;350:132–134. doi: 10.1111/j.1600-0447.1989.tb07192.x. [DOI] [PubMed] [Google Scholar]
  38. Guy W., Wilson W. H., Ban T. A., King D. L., Manov G., Fjetland O. K. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull. 1984 Winter;20(1):73–78. [PubMed] [Google Scholar]
  39. Harrison G. New or old antidepressants? New is better. BMJ. 1994 Nov 12;309(6964):1280–1281. doi: 10.1136/bmj.309.6964.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Jick S. S., Dean A. D., Jick H. Antidepressants and suicide. BMJ. 1995 Jan 28;310(6974):215–218. doi: 10.1136/bmj.310.6974.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Johnson D. A. Depression: treatment compliance in general practice. Acta Psychiatr Scand Suppl. 1981;290:447–453. doi: 10.1111/j.1600-0447.1981.tb00751.x. [DOI] [PubMed] [Google Scholar]
  42. Judd F. K., Moore K., Norman T. R., Burrows G. D., Gupta R. K., Parker G. A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatry. 1993 Mar;27(1):49–55. doi: 10.3109/00048679309072123. [DOI] [PubMed] [Google Scholar]
  43. Jönsson B., Bebbington P. E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994 May;164(5):665–673. doi: 10.1192/bjp.164.5.665. [DOI] [PubMed] [Google Scholar]
  44. Kasper S., Fuger J., Möller H. J. Comparative efficacy of antidepressants. Drugs. 1992;43 (Suppl 2):11–23. doi: 10.2165/00003495-199200432-00004. [DOI] [PubMed] [Google Scholar]
  45. Keegan D., Bowen R. C., Blackshaw S., Saleh S., Dayal N., Remillard F., Shrikhande S., Cebrian Perez S., Boulton A. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol. 1991 Summer;6(2):117–124. doi: 10.1097/00004850-199100620-00007. [DOI] [PubMed] [Google Scholar]
  46. Klok C. J., Brouwer G. J., van Praag H. M., Doogan D. Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study. Acta Psychiatr Scand. 1981 Jul;64(1):1–11. doi: 10.1111/j.1600-0447.1981.tb00756.x. [DOI] [PubMed] [Google Scholar]
  47. Kuhs H., Rudolf G. A. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand Suppl. 1989;350:145–146. doi: 10.1111/j.1600-0447.1989.tb07198.x. [DOI] [PubMed] [Google Scholar]
  48. Laakmann G., Blaschke D., Engel R., Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry Suppl. 1988 Sep;(3):64–68. [PubMed] [Google Scholar]
  49. Lapierre Y. D., Browne M., Horn E., Oyewumi L. K., Sarantidis D., Roberts N., Badoe K., Tessier P. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry. 1987 Feb;48(2):65–68. [PubMed] [Google Scholar]
  50. Laursen A. L., Mikkelsen P. L., Rasmussen S., le Fèvre Honoré P. Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. Acta Psychiatr Scand. 1985 Mar;71(3):249–255. doi: 10.1111/j.1600-0447.1985.tb01281.x. [DOI] [PubMed] [Google Scholar]
  51. Levine S., Deo R., Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Br J Psychiatry. 1987 May;150:653–655. doi: 10.1192/bjp.150.5.653. [DOI] [PubMed] [Google Scholar]
  52. Levine S., Deo R., Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):41–45. [PubMed] [Google Scholar]
  53. Loeb C., Albano C., Gandolfo C. Fluoxetine versus imipramine. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):75–79. [PubMed] [Google Scholar]
  54. Lydiard R. B., Laird L. K., Morton W. A., Jr, Steele T. E., Kellner C., Laraia M. T., Ballenger J. C. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989;25(1):68–70. [PubMed] [Google Scholar]
  55. Manna V., Martucci N., Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):81–88. [PubMed] [Google Scholar]
  56. March J. S., Kobak K. A., Jefferson J. W., Mazza J., Greist J. H. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry. 1990 May;51(5):200–202. [PubMed] [Google Scholar]
  57. Mertens C., Pintens H. Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Acta Psychiatr Scand. 1988 Jun;77(6):683–688. doi: 10.1111/j.1600-0447.1988.tb05188.x. [DOI] [PubMed] [Google Scholar]
  58. Montgomery S. A., Henry J., McDonald G., Dinan T., Lader M., Hindmarch I., Clare A., Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994 Spring;9(1):47–53. doi: 10.1097/00004850-199400910-00008. [DOI] [PubMed] [Google Scholar]
  59. Muijen M., Roy D., Silverstone T., Mehmet A., Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand. 1988 Sep;78(3):384–390. doi: 10.1111/j.1600-0447.1988.tb06353.x. [DOI] [PubMed] [Google Scholar]
  60. Mullin J. M., Pandita-Gunawardena V. R., Whitehead A. M. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract. 1988 Feb;42(2):51–55. [PubMed] [Google Scholar]
  61. Möller H. J., Berzewski H., Eckmann F., Gonzalves N., Kissling W., Knorr W., Ressler P., Rudolf G. A., Steinmeyer E. M., Magyar I. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry. 1993 May;26(3):75–78. doi: 10.1055/s-2007-1014346. [DOI] [PubMed] [Google Scholar]
  62. Nathan R. S., Perel J. M., Pollock B. G., Kupfer D. J. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry. 1990 Sep;51(9):367–372. [PubMed] [Google Scholar]
  63. Nielsen B. M., Behnke K., Arup P., Christiansen P. E., Geisler A., Ipsen E., Maach-Møller B., Ohrberg S. C. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand. 1993 Apr;87(4):269–272. doi: 10.1111/j.1600-0447.1993.tb03370.x. [DOI] [PubMed] [Google Scholar]
  64. Nielsen O. A., Morsing I., Petersen J. S., Larsen T., Møller S. E., Manniche P. M., Skausig O. B. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatr Scand. 1991 Sep;84(3):233–241. doi: 10.1111/j.1600-0447.1991.tb03136.x. [DOI] [PubMed] [Google Scholar]
  65. Norton K. R., Sireling L. I., Bhat A. V., Rao B., Paykel E. S. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Disord. 1984 Dec;7(3-4):297–308. doi: 10.1016/0165-0327(84)90051-x. [DOI] [PubMed] [Google Scholar]
  66. Noyes R., Jr Suicide and panic disorder: a review. J Affect Disord. 1991 May-Jun;22(1-2):1–11. doi: 10.1016/0165-0327(91)90077-6. [DOI] [PubMed] [Google Scholar]
  67. Ohrberg S., Christiansen P. E., Severin B., Calberg H., Nilakantan B., Borup A., Søgaard J., Larsen S. B., Loldrup D., Bahr B. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand. 1992 Dec;86(6):437–444. doi: 10.1111/j.1600-0447.1992.tb03294.x. [DOI] [PubMed] [Google Scholar]
  68. Owens D. New or old antidepressants? Benefits of new drugs are exaggerated. BMJ. 1994 Nov 12;309(6964):1281–1282. doi: 10.1136/bmj.309.6964.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Paykel E. S., Priest R. G. Recognition and management of depression in general practice: consensus statement. BMJ. 1992 Nov 14;305(6863):1198–1202. doi: 10.1136/bmj.305.6863.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Perez A., Ashford J. J. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin. 1990;12(4):234–241. doi: 10.1185/03007999009111652. [DOI] [PubMed] [Google Scholar]
  71. Perry P. J., Garvey M. J., Kelly M. W., Cook B. L., Dunner F. J., Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry. 1989 Aug;50(8):290–294. [PubMed] [Google Scholar]
  72. Peselow E. D., Filippi A. M., Goodnick P., Barouche F., Fieve R. R. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull. 1989;25(2):267–271. [PubMed] [Google Scholar]
  73. Phanjoo A. L., Wonnacott S., Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand. 1991 Jun;83(6):476–479. doi: 10.1111/j.1600-0447.1991.tb05579.x. [DOI] [PubMed] [Google Scholar]
  74. Poelinger W., Haber H. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):47–50. [PubMed] [Google Scholar]
  75. Rahman M. K., Akhtar M. J., Savla N. C., Sharma R. R., Kellett J. M., Ashford J. J. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract. 1991 Winter;45(4):255–258. [PubMed] [Google Scholar]
  76. Reimherr F. W., Chouinard G., Cohn C. K., Cole J. O., Itil T. M., LaPierre Y. D., Masco H. L., Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990 Dec;51 (Suppl B):18–27. [PubMed] [Google Scholar]
  77. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):89–95. [PubMed] [Google Scholar]
  78. Roth D., Mattes J., Sheehan K. H., Sheehan D. V. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(6):929–939. doi: 10.1016/0278-5846(90)90078-u. [DOI] [PubMed] [Google Scholar]
  79. Sinclair J. C., Bracken M. B. Clinically useful measures of effect in binary analyses of randomized trials. J Clin Epidemiol. 1994 Aug;47(8):881–889. doi: 10.1016/0895-4356(94)90191-0. [DOI] [PubMed] [Google Scholar]
  80. Song F., Freemantle N., Sheldon T. A., House A., Watson P., Long A., Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993 Mar 13;306(6879):683–687. doi: 10.1136/bmj.306.6879.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Stark P., Hardison C. D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):53–58. [PubMed] [Google Scholar]
  82. Tamminen T. T., Lehtinen V. V. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):51–56. [PubMed] [Google Scholar]
  83. Taneri Z., Köhler R. Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):57–61. [PubMed] [Google Scholar]
  84. Wilson A., Henry D. A. Meta-analysis. Part 2: Assessing the quality of published meta-analyses. Med J Aust. 1992 Feb 3;156(3):173-4, 177-80, 184-7. [PubMed] [Google Scholar]
  85. Young J. P., Coleman A., Lader M. H. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br J Psychiatry. 1987 Sep;151:337–340. doi: 10.1192/bjp.151.3.337. [DOI] [PubMed] [Google Scholar]
  86. de Jonghe F., Ravelli D. P., Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991 Mar;24(2):62–67. doi: 10.1055/s-2007-1014440. [DOI] [PubMed] [Google Scholar]
  87. de Jonghe F., Swinkels J., Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 1991 Jan;24(1):21–27. doi: 10.1055/s-2007-1014428. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES